Hadrich Dirk
European Commission, Innovative and Personalised Medicine Unit, Health Directorate, Directorate-General Research and Innovation, Brussels, Belgium.
Front Genet. 2018 Jun 13;9:212. doi: 10.3389/fgene.2018.00212. eCollection 2018.
The human microbiome has emerged as the crucial moderator in the interactions between food and our body. It is increasingly recognised that the microbiome can change our mind and health status, or switch on a wide range of diseases including cancer, cardio-metabolic diseases, allergies, and obesity. The causes of diseases are often only partially understood. However, nutrients, metabolites, and microbes are increasingly regarded as key players, even where the complete disease mechanisms remain unclear. The key to progress in the future will be to use and exploit additional, newly emerging disciplines such as metagenomics to complement patient information and to bring our understanding of diseases and the interrelation and effects of nutritional molecules to the next level. The EU has already funded 216 projects under the 7th Framework Programme and Horizon 2020 programmes to promote metagenomics and to advance our knowledge of microbes. This support started with the catalysing MetaHIT project that has produced a catalogue of gut microbes, and has arrived now at the very multi-disciplinary SYSCID action looking at how the microbiome is driving its resilience potential and our health. Together, these projects involve an investment of more than €498 M. However, in Horizon 2020, the new EU Health and Food Work Programmes for 2018-2020 go even further by setting new goals to find applications and to generate more knowledge on the microbiome, nutrition, various hosts of microbes, and their relation to health and disease. The big vision is to modulate health and diseases via the microbiome and nutrition, while at the same time other factors such as omics, molecular signatures, and lifestyle are constant. In this way, microbiome and nutrition research is moving from an isolated and despised offside position to a beacon of hope with a lot of potential and possibilities.
人类微生物组已成为食物与人体之间相互作用的关键调节者。人们越来越认识到,微生物组能够改变我们的思维和健康状况,或者引发包括癌症、心血管代谢疾病、过敏和肥胖在内的多种疾病。疾病的成因往往只是部分为人所知。然而,营养素、代谢物和微生物越来越被视为关键因素,即便完整的疾病机制仍不明确。未来取得进展的关键将是利用和开发诸如宏基因组学等新兴学科,以补充患者信息,并将我们对疾病以及营养分子的相互关系和作用的理解提升到新的高度。欧盟已在第七框架计划和“地平线2020”计划下资助了216个项目,以促进宏基因组学发展并增进我们对微生物的了解。这种支持始于具有催化作用的MetaHIT项目,该项目编制了一份肠道微生物目录,如今已发展到非常多学科的SYSCID行动,研究微生物组如何发挥其恢复力潜力以及对我们健康的影响。这些项目总共涉及超过4.98亿欧元的投资。然而,在“地平线2020”计划中,欧盟2018 - 2020年新的健康与食品工作计划走得更远,设定了新目标,以寻找微生物组、营养、各种微生物宿主及其与健康和疾病关系的应用并生成更多知识。宏伟愿景是通过微生物组和营养来调节健康与疾病,同时其他因素如组学、分子特征和生活方式保持不变。通过这种方式,微生物组和营养研究正从一个孤立且被轻视的边缘地位转变为一个充满潜力和可能性的希望灯塔。